secwatch.observer — SEC 8-K summary
======================================

Issuer:     HAEMONETICS CORP (HAE)
CIK:        0000313143
Form:       8-K
Filed at:   2022-03-21T23:59:59+00:00
Accession:  0000313143-22-000015
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Haemonetics appoints James D'Arecca as CFO effective April 11, 2022; Burke to retire
--------------------------------------------------------------------------------

- James D'Arecca appointed CFO effective April 11, 2022; William Burke steps down as CFO on that date.
- D'Arecca previously CFO at TherapeuticsMD; prior roles at Allergan, Bausch & Lomb, Merck, PwC.
- Compensation: $525k base salary, 75% target bonus, $1.1M LTI target, $400k sign-on bonus.
- Initial equity grant valued at $600k: 50% RSUs, 50% options, vesting 25% annually over 4 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/313143/000031314322000015/0000313143-22-000015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/313143/000031314322000015/hae-20220321.htm
  HTML page:      https://secwatch.observer/filing/0000313143-22-000015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer